827 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B Downtrend
Article Searches
Merck & Co. (MRK) Q4 2018 Earnings Conference Call Transcript https://www.fool.com/earnings/call-transcripts/2019/02/01/merck-co-mrk-q4-2018-earnings-conference-call-tran.aspx?source=iedfolrf0000001 Feb 01, 2019 - MRK earnings call for the period ending December 31, 2018.
Merck & Co Inc. (MRK) Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4237499-merck-and-co-inc-mrk-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare Feb 01, 2019 - Merck & Co Inc. (NYSE:MRK) Q4 2018 Earnings Conference Call February 01, 2019 08:00 AM ET Company Participants Teri Loxam - IR Ken Frazier - Chairman and CEO Rob Davis - CFO Roger Perlmutter - Pre
Merck (MRK) Tops on Q4 Earnings & Sales, Stock Up http://www.zacks.com/stock/news/351474/merck-mrk-tops-on-q4-earnings-sales-stock-up?cid=CS-ZC-FT-351474 Feb 01, 2019 - Merck (MRK) beats estimates for earnings as well as sales in fourth-quarter 2018. Stock is up in pre-market trading.
What's in the Cards for Skyworks (SWKS) in Q1 Earnings? http://www.zacks.com/stock/news/351009/whats-in-the-cards-for-skyworks-swks-in-q1-earnings?cid=CS-ZC-FT-351009 Jan 31, 2019 - Skyworks (SWKS) is benefiting from its portfolio strength, particularly in the 5G applications and IoT market.
Roche Halts Two Late-Stage Studies on Alzheimer's Candidate http://www.zacks.com/stock/news/350873/roche-halts-two-late-stage-studies-on-alzheimers-candidate?cid=CS-ZC-FT-350873 Jan 30, 2019 - Roche (RHHBY) discontinues two phase III studies evaluating its anti-beta-amyloid molecule, crenezumab in people with early sporadic Alzheimer's disease.
A Cure for Cancer Next Year? The Stock Market Says Don't Believe the Hype https://www.fool.com/investing/2019/01/30/a-cure-for-cancer-next-year-the-stock-market-says.aspx?source=iedfolrf0000001 Jan 30, 2019 - Israeli scientists claim they have a cure for cancer. Investors' response? The proof is in the pudding.
Why Merck (MRK) Could Beat Earnings Estimates Again http://www.zacks.com/stock/news/350358/why-merck-mrk-could-beat-earnings-estimates-again?cid=CS-ZC-FT-350358 Jan 29, 2019 - Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
MRK: BMO Capital Markets cuts to Market Perform http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=UD20190125123740 Jan 25, 2019 - BMO Capital Markets issues rating change for MRK
Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV http://www.zacks.com/stock/news/349786/pharma-stock-roundup-jnj-bmys-q4-earnings-study-failures-at-lly-abbv?cid=CS-ZC-FT-349786 Jan 25, 2019 - J&J (JNJ) and Bristol-Myers (BMY) kick off earnings for pharma sector. Lilly (LLY) and AbbVie (ABBV) announce failure of late-stage studies.
Amgen/Allergan's Rituxan Biosimilar Meets Goal in Phase III http://www.zacks.com/stock/news/349758/amgen-allergans-rituxan-biosimilar-meets-goal-in-phase-iii?cid=CS-ZC-FT-349758 Jan 25, 2019 - Amgen (AMGN) along with partner Allergan reports upbeat top-line data from a phase I/III study on ABP 798, a biosimilar candidate of Roche???s Rituxan. The program achieves the primary endpoint.

Pages: 1...56789101112131415...83

<<<Page 10>